RxSight Inc. (RXST)
NASDAQ: RXSTHealth CareOphthalmic GoodsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RXST stock chart
Technical analysisKey statistics
All statistics- Market cap
- $187.42M
- EPS (TTM)
- -$1.29
- Dividend yield
- None
- 52-week range
- 4.11 – 13.22
- Day range
- 4.45 – 4.75
- Volume / Avg
- 539.31K / 826.96K
- Beta
- —
- Shares outstanding
- 41.93M
52-week range
RXST stock today
RxSight (RXST) closed at $4.47 on Nov 20, down 3.04% (-$0.14), versus the S&P 500's 3.70% decline. Shares are 66.2% below their 52-week high of $13.22, set on Dec 11, 2025 and 8.8% above the 52-week low of $4.11, near the bottom of the past year's range. RXST is down 57.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.0%.
RxSight has posted a net loss over the last twelve months (EPS of -$1.29), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About RxSight
Company profileRxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- CEO
- Mr. Aziz Mottiwala M.B.A.
- Headquarters
- Aliso Viejo, CA
- Employees
- 461
- IPO year
- 2021
- Website
- rxsight.com
Financial highlights
Full financialsIn fiscal 2025, RxSight generated $134.5 million in revenue, down 3.9% from fiscal 2024, the first decline in the 6 years shown. RxSight reported a net loss of $38.9 million, compared with a loss of $27.5 million a year earlier. Gross margin was 76.6% (up from 70.7%) and operating margin -35.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $134.48M | $139.93M | $89.08M | $49.01M | $22.59M |
| Growth | -3.89% | +57.09% | +81.77% | +116.90% | +53.92% |
| Net income | $-38.94M | $-27.45M | $-48.61M | $-66.76M | $-48.69M |
| EPS (diluted) | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
Analyst forecast
ForecastConsensus (10 analysts)
hold
Avg. price target
$6.10+36.47%
- Strong buy 1
- Buy 0
- Hold 7
- Sell 0
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.39 vs $-0.42
- Surprise
- +7.14%
RXST news
All RXST news- RxSight, Inc. to Present at the Piper Sandler Healthcare ConferenceGlobeNewswire
- RxSight (RXST) Q3 2026 Earnings Call TranscriptNasdaq
- RxSight, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
- RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue EstimatesNasdaqRXST, GMED
- RxSight, Inc. Reports Third Quarter 2026 ResultsGlobeNewswire
- RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing RulesGlobeNewswire
- RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3GlobeNewswire
- RxSight Appoints Eye Care Industry Leaders to Drive Commercial TransformationGlobeNewswire
RxSight peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LUCYInnovative Eyewear Inc. | 0.7025 | -0.07% | $6.12M | vs RXST |
| STAASTAAR Surgical Company | 24.22 | -3.24% | $1.22B | vs RXST |
| EYENational Vision Holdings Inc. | 16.72 | -1.70% | $1.31B | vs RXST |
| WRBYWarby Parker Inc. Class A | 23.12 | -4.19% | $2.87B | vs RXST |
| BLCOBausch + Lomb Corporation | 19.38 | -6.33% | $6.93B | vs RXST |
| COOThe Cooper Companies Inc. | 58.88 | -2.40% | $11.20B | vs RXST |
| ALCAlcon Inc. | 74.31 | -0.26% | $35.70B | vs RXST |
Indexes, lists and sector
RxSight stock FAQ
What is RxSight's stock price today?
RXST last traded at $4.47 as of Nov 20, 4:00 PM EST, down 3.04% on the day. Prices are delayed at least 15 minutes.
Who is RxSight's CEO?
Mr. Aziz Mottiwala M.B.A. is the chief executive officer of RxSight Inc., which has about 461 employees.
What is the RXST 52-week high?
The 52-week high for RXST is $13.22 and the 52-week low is $4.11. The stock is currently 66.2% below its high.